Elsevier

The Lancet

Volume 352, Issue 9131, 12 September 1998, Pages 835-836
The Lancet

Commentary
Gains and losses from dexamethasone for neonatal chronic lung disease

https://doi.org/10.1016/S0140-6736(05)60002-5Get rights and content

References (20)

  • BS Brozanski et al.

    Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birthweight infant

    J Pediatr

    (1995)
  • Dexamethasone therapy in neonatal chronic lung disease: an international, placebo-controlled trial

    Pediatrics

    (1991)
  • ES Shinwell et al.

    Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome

    Arch Dis Child

    (1996)
  • A Rastogi et al.

    A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant treated infants

    Pediatrics

    (1996)
  • TF Yeh et al.

    Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicentre clinical trial

    Pediatrics

    (1997)
  • RB D'Agostino et al.

    Meta-analysis: a method for synthesising research

    Clin Pharmacol Ther

    (1995)
  • E Bancalari

    Corticosteroids and neonatal chronic lung disease

    Eur J Pediatr

    (1998)
  • T Bhuta et al.

    Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease

    Arch Dis Child

    (1998)
  • RJ Sanders et al.

    Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome

    Pediatr Res

    (1994)
  • L Kovacs et al.

    Efficacy of sequential early systematic and inhaled corticosteroid therapy in the prevention of chronic lung disease on prematurity

    Acta Pediatr

    (1998)
There are more references available in the full text version of this article.

Cited by (18)

  • Neonatal ventilation strategies and long-term respiratory outcomes

    2014, Early Human Development
    Citation Excerpt :

    This can lead to asynchrony, active expiration and air leaks [23]. Asynchrony and air leaks can be reduced by the administration of neuromuscular blocking agents [24], but then higher peak pressures are required and infants can become oedematous. An alternative approach to abolish asynchrony is to use fast ventilator rates (60–120/min high-frequency positive pressure ventilation, HFPPV), which more closely reflects the infant's spontaneous respiratory rate; meta-analysis of the results of RCTs [25] show that HFPPV compared to slower rate PLV significantly reduces air leaks (RR, 0.69; 95% CI, 0.51–0.93), but only in prematurely born infants [9,11].

  • Pulmonary Outcome and Follow-Up

    2011, Assisted Ventilation of the Neonate
  • Bacterial Infections of the Respiratory Tract

    2011, Infectious Diseases of the Fetus and Newborn Infant
  • Pulmonary outcome and follow-up

    2010, Assisted Ventilation of the Neonate: Expert Consult - Online and Print
  • Bacterial infections of the respiratory tract

    2010, Infectious Diseases of the Fetus and Newborn: Expert Consult - Online and Print
  • Bacterial Infections of the Respiratory Tract

    2006, Infectious Diseases of the Fetus and Newborn Infant
View all citing articles on Scopus
View full text